{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:21:00Z","timestamp":1765484460550,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","award":["2024SF57"],"award-info":[{"award-number":["2024SF57"]}],"id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clon.2025.103781","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T02:27:03Z","timestamp":1738376823000},"page":"103781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Does the Presence of Ductal Carcinoma in situ Affect Prognostic Outcomes After Neoadjuvant Therapy in Invasive Ductal Carcinoma of the Breast?"],"prefix":"10.1016","volume":"40","author":[{"given":"S.","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clon.2025.103781_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/cancers15010013","article-title":"Pathologic Response of Associated Ductal Carcinoma in situ to Neoadjuvant Systemic Therapy: A Systematic Review","volume":"15","author":"Wazir","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.clon.2025.103781_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10549-023-07012-z","article-title":"Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis","volume":"201","author":"Ploumen","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.clon.2025.103781_bib3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10549-011-1621-0","article-title":"Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy\/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)","volume":"132","author":"von Minckwitz","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clon.2025.103781_bib4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/his.12796","article-title":"Ductal carcinoma in situ-update on risk assessment and management","volume":"68","author":"Pang","year":"2016","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.clon.2025.103781_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/jso.20242","article-title":"Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins","volume":"90","author":"Dzierzanowski","year":"2005","journal-title":"J\u00a0Surg Oncol"},{"issue":"9","key":"10.1016\/j.clon.2025.103781_bib6","article-title":"Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective","volume":"5","author":"Lee","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"issue":"13","key":"10.1016\/j.clon.2025.103781_bib7","doi-asserted-by":"crossref","first-page":"11181","DOI":"10.1007\/s00432-023-04895-9","article-title":"Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ","volume":"149","author":"Liu","year":"2023","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.clon.2025.103781_bib8","article-title":"Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials","volume":"15","author":"Fazal","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.clon.2025.103781_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.12703\/r\/10-2","article-title":"Recent advances in neoadjuvant therapy for breast cancer","volume":"10","author":"Potter","year":"2021","journal-title":"Fac Rev"},{"key":"10.1016\/j.clon.2025.103781_bib10","first-page":"199","article-title":"Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer","volume":"13","author":"Hyder","year":"2021","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"1","key":"10.1016\/j.clon.2025.103781_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJMe1603691","article-title":"I-SPY 2-Toward More Rapid Progress in Breast Cancer Treatment","volume":"375","author":"Carey","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.clon.2025.103781_bib12","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1200\/JCO.2006.08.2271","article-title":"Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome","volume":"25","author":"Mazouni","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.clon.2025.103781_bib13","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.clon.2017.06.003","article-title":"Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice","volume":"29","author":"Cain","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"8","key":"10.1016\/j.clon.2025.103781_bib14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ejso.2017.04.011","article-title":"Chemotherapy may eradicate ductal carcinoma in situ (DCIS) but not the associated microcalcifications","volume":"43","author":"Goldberg","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.clon.2025.103781_bib15","doi-asserted-by":"crossref","first-page":"9934","DOI":"10.1038\/s41598-019-46309-2","article-title":"Overall survival is improved when DCIS accompanies invasive breast cancer","volume":"9","author":"Kole","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.clon.2025.103781_bib16","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.breast.2014.03.008","article-title":"Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status","volume":"23","author":"Tanioka","year":"2014","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.clon.2025.103781_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.clbc.2020.01.011","article-title":"Improved Prognostication for the Updated AJCC Breast Cancer Pathological Prognostic Staging Varied in Higher-Stage Groups","volume":"20","author":"Hu","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clon.2025.103781_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21037\/tbcr-22-21","article-title":"CSCO BC guideline working group. Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022","volume":"3","author":"Jiang","year":"2022","journal-title":"Transl Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.clon.2025.103781_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10549-024-07270-5","article-title":"Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer","volume":"205","author":"Kaplan","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clon.2025.103781_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10549-021-06235-2","article-title":"Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer","volume":"189","author":"Groen","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.clon.2025.103781_bib21","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/annonc\/mdt131","article-title":"Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer","volume":"24","author":"Kim","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clon.2025.103781_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/bjc.2015.426","article-title":"Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort","volume":"114","author":"Hamy","year":"2016","journal-title":"Br J Cancer"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655525000366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655525000366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:35:52Z","timestamp":1762331752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655525000366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":22,"alternative-id":["S0936655525000366"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2025.103781","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does the Presence of Ductal Carcinoma in situ Affect Prognostic Outcomes After Neoadjuvant Therapy in Invasive Ductal Carcinoma of the Breast?","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2025.103781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}],"article-number":"103781"}}